On June 4, 2026, Imunon, Inc. (IMNN) announced a financing that is expected to provide up to $10 million in aggregate proceeds. The financing includes 250 shares of non-redeemable, non-convertible preferred stock for $2.5 million and two secured promissory notes in the principal amounts of $2.72 million and $5.0 million. Importantly, there are no warrants or other dilutive overhangs. The financing will be used in part by the company to continue enrolling the ongoing Phase 3 OVATION 3 trial that is testing IMNN-001 in women with newly diagnosed advanced ovarian cancer.
